Sharon Mates - 21 Aug 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Signature
/s/ John P. Condon, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
21 Aug 2024
Net transactions value
-$6,959,486
Form type
4
Filing time
23 Aug 2024, 18:00:20 UTC
Previous filing
25 Apr 2024
Next filing
28 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $931,438 +53,013 +5% $17.57 1,123,342 21 Aug 2024 Direct
transaction ITCI Common Stock Sale $3,327,818 -44,134 -3.9% $75.40 1,079,208 21 Aug 2024 Direct F1, F2
transaction ITCI Common Stock Sale $327,432 -4,297 -0.4% $76.20 1,074,911 21 Aug 2024 Direct F1, F3
transaction ITCI Common Stock Sale $207,088 -2,682 -0.25% $77.21 1,072,229 21 Aug 2024 Direct F1, F4
transaction ITCI Common Stock Sale $148,163 -1,900 -0.18% $77.98 1,070,329 21 Aug 2024 Direct F1, F5
transaction ITCI Common Stock Options Exercise $691,907 +39,380 +3.7% $17.57 1,109,709 22 Aug 2024 Direct
transaction ITCI Common Stock Sale $2,611,075 -35,011 -3.2% $74.58 1,074,698 22 Aug 2024 Direct F1, F6
transaction ITCI Common Stock Sale $329,727 -4,369 -0.41% $75.47 1,070,329 22 Aug 2024 Direct F1, F7
transaction ITCI Common Stock Options Exercise $503,908 +28,680 +2.7% $17.57 1,099,009 23 Aug 2024 Direct
transaction ITCI Common Stock Sale $2,135,435 -28,680 -2.6% $74.46 1,070,329 23 Aug 2024 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -53,013 -24% $0.000000 163,985 21 Aug 2024 Common Stock 53,013 $17.57 Direct F9
transaction ITCI Stock Option (right to buy) Options Exercise $0 -39,380 -24% $0.000000 124,605 22 Aug 2024 Common Stock 39,380 $17.57 Direct F9
transaction ITCI Stock Option (right to buy) Options Exercise $0 -28,680 -23% $0.000000 95,925 23 Aug 2024 Common Stock 28,680 $17.57 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.90 to $76.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.975 to $77.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.905 to $78.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.28 to $75.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.30 to $75.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.16 to $74.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F9 This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested.

Remarks:

EX-24.1 - Power of Attorney